Compare Stocks: ENZN, HYBT, BLRX, and PHIO

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.78 +2.0%	$3.09	$2.15 ▼ $4.56	$11.87M	1.54	9,068 shs	15,644 shs
ENZN Enzon Pharmaceuticals	$4.35	$4.94	$1.50 ▼ $9.50	$3.23M	-0.05	1,513 shs	N/A
HYBT Heyu Biological Technology	$0.14	$0.12	$0.00 ▼ $3.40	$14.22M	-17.74	5,371 shs	N/A
PHIO Phio Pharmaceuticals	$1.06 -0.9%	$1.04	$0.81 ▼ $4.19	$12.43M	0.82	1.54 million shs	50,609 shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	+1.08%	-1.09%	-13.92%	-12.26%	-30.08%
ENZN Enzon Pharmaceuticals	0.00%	0.00%	0.00%	-28.79%	-45.56%
HYBT Heyu Biological Technology	0.00%	0.00%	0.00%	-31.43%	+59,900.00%
PHIO Phio Pharmaceuticals	+0.94%	+8.72%	+8.08%	-6.14%	-54.47%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BLRX BioLineRx	$2.78 +2.0%	$3.09	$2.15 ▼ $4.56	$11.87M	1.54	9,068 shs	15,644 shs
ENZN Enzon Pharmaceuticals	$4.35	$4.94	$1.50 ▼ $9.50	$3.23M	-0.05	1,513 shs	N/A
HYBT Heyu Biological Technology	$0.14	$0.12	$0.00 ▼ $3.40	$14.22M	-17.74	5,371 shs	N/A
PHIO Phio Pharmaceuticals	$1.06 -0.9%	$1.04	$0.81 ▼ $4.19	$12.43M	0.82	1.54 million shs	50,609 shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BLRX BioLineRx	+1.08%	-1.09%	-13.92%	-12.26%	-30.08%
ENZN Enzon Pharmaceuticals	0.00%	0.00%	0.00%	-28.79%	-45.56%
HYBT Heyu Biological Technology	0.00%	0.00%	0.00%	-31.43%	+59,900.00%
PHIO Phio Pharmaceuticals	+0.94%	+8.72%	+8.08%	-6.14%	-54.47%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BLRX BioLineRx	1.00	Sell	N/A	N/A
ENZN Enzon Pharmaceuticals	0.00	N/A	N/A	N/A
HYBT Heyu Biological Technology	0.00	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	2.00	Hold	$14.00	1,220.75% Upside

Current Analyst Ratings Breakdown

Latest ENZN, HYBT, BLRX, and PHIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
7/17/2026	BLRX BioLineRx	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/17/2026	PHIO Phio Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)

(Data available from 8/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BLRX BioLineRx	$1.18M	10.28	N/A	N/A	$5.36 per share	0.52
ENZN Enzon Pharmaceuticals	$30K	107.59	N/A	N/A	($3.40) per share	-1.28
HYBT Heyu Biological Technology	$80K	177.78	N/A	N/A	$0.38 per share	0.36
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	$1.87 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BLRX BioLineRx	-$1.17M	-$1.92	N/A	N/A	N/A	-563.70%	-37.73%	-19.42%	8/13/2026 (Estimated)
ENZN Enzon Pharmaceuticals	-$3.41M	-$6.84	N/A	N/A	N/A	N/A	-21.54%	-7.22%	N/A
HYBT Heyu Biological Technology	-$270K	N/A	N/A	N/A	N/A	-453.55%	-6.43%	-4.43%	N/A
PHIO Phio Pharmaceuticals	-$8.70M	-$1.38	N/A	N/A	N/A	N/A	-77.34%	-70.87%	8/6/2026 (Estimated)

Latest ENZN, HYBT, BLRX, and PHIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	BLRX BioLineRx	-$0.15	N/A	N/A	N/A	$0.43 million	N/A
8/6/2026	Q2 2026	PHIO Phio Pharmaceuticals	-$0.36	-$0.36	N/A	-$0.36	N/A	N/A
5/27/2026	Q1 2026	BLRX BioLineRx	-$1.04	-$0.36	+$0.68	N/A	$0.34 million	$0.48 million
5/7/2026	Q1 2026	PHIO Phio Pharmaceuticals	-$0.24	-$0.34	-$0.10	-$0.34	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BLRX BioLineRx	N/A	N/A	N/A	N/A	N/A
ENZN Enzon Pharmaceuticals	$0.12	2.76%	N/A	N/A	N/A
HYBT Heyu Biological Technology	N/A	N/A	N/A	N/A	N/A
PHIO Phio Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BLRX BioLineRx	0.16	1.58	1.43
ENZN Enzon Pharmaceuticals	0.42	2.01	1.16
HYBT Heyu Biological Technology	N/A	0.35	0.34
PHIO Phio Pharmaceuticals	N/A	18.32	18.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BLRX BioLineRx	1.56%
ENZN Enzon Pharmaceuticals	N/A
HYBT Heyu Biological Technology	N/A
PHIO Phio Pharmaceuticals	57.31%

Insider Ownership

Company	Insider Ownership
BLRX BioLineRx	1.10%
ENZN Enzon Pharmaceuticals	0.40%
HYBT Heyu Biological Technology	89.24%
PHIO Phio Pharmaceuticals	0.89%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BLRX BioLineRx	40	4.37 million	4.32 million	Optionable
ENZN Enzon Pharmaceuticals	N/A	742,000	739,000	Not Optionable
HYBT Heyu Biological Technology	6	103.25 million	11.11 million	Not Optionable
PHIO Phio Pharmaceuticals	10	11.62 million	11.51 million	Not Optionable

ENZN, HYBT, BLRX, and PHIO Headlines

Recent News About These Companies

Phio Pharmaceuticals Reports Second Quarter 2026 Financial Results and Business Update

August 6 at 4:05 PM | newsfilecorp.comN

Correction to Announcement Regarding Phio Pharmaceuticals Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

July 22, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Appointment of Dr. R. Todd Plott to the Board of Directors

July 21, 2026 | newsfilecorp.comN

Phio Pharmaceuticals expands global patent portfolio with new international patent milestones

July 15, 2026 | msn.com

Phio Pharmaceuticals Announces Patent Milestone with Multiple Notices of Allowance and Grant Decision

July 15, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

June 26, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces "How siRNA Therapy can Change the Course of Cancer Treatment" in a Fireside Chat with Force Family Office on Monday, June 29, 2026

June 25, 2026 | finance.yahoo.com

Phio Pharmaceuticals Reaches Key Milestone in Advancing Lead Candidate PH-762

June 24, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Participation in the Life Sciences Investor Forum on June 24-25, 2026

June 18, 2026 | finance.yahoo.com

Phio Pharmaceuticals to Participate in the Renmark Financial Communications Live Virtual Non-Deal Roadshow Series

May 27, 2026 | tennessean.comT

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 8, 2026 | finanznachrichten.de

Phio Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update

May 7, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15 ...

April 14, 2026 | finanznachrichten.de

Phio Pharmaceuticals Announces "Nobel Prize Winning Science Takes on Skin Cancer" in a Fireside Chat with Force Family Office on Wednesday, April 15, 2026

April 13, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces Presentation at Centri Capital Conference on April 14, 2026

April 9, 2026 | finance.yahoo.com

Pyramid Pharma Services Announces Drug Product Manufacturing Agreement for Phio Pharmaceuticals’ Lead Oncology Candidate

April 8, 2026 | jsonline.comJ

Phio Pharmaceuticals Corp.: Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

March 31, 2026 | finanznachrichten.de

Phio Pharmaceuticals Announces Agreement with U.S. cGMP Manufacturing Source for Drug Product, PH-762

March 30, 2026 | newsfilecorp.comN

Phio Pharmaceuticals Announces American Academy of Dermatology 2026 Presentation Featuring Clinical Study Results from Study of PH-762 for Cutaneous Carcinoma Underscoring ...

March 23, 2026 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENZN, HYBT, BLRX, and PHIO Company Descriptions

BioLineRx NASDAQ:BLRX

$2.78 +0.06 (+2.02%)

Closing price 03:32 PM Eastern

Extended Trading

$2.78 0.00 (0.00%)

As of 04:10 PM Eastern

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma. It also develops BL-5010, a pen-like applicator containing an acidic aqueous solution for the non-surgical removal of skin lesions. BioLineRx Ltd. was incorporated in 2003 and is headquartered in Hevel Modi'in, Israel.

Enzon Pharmaceuticals OTCMKTS:ENZN

$4.35 0.00 (0.00%)

As of 08/5/2026

Enzon Pharmaceuticals, Inc., together with its subsidiaries, does not have significant operations. Previously, the company marketed its patented drug product, PegIntron. It also had a marketing agreement with Micromet AG relating to the Vicineum drug; and a licensing agreement regarding SC Oncaspar and certain other drugs. The company was formerly known as Enzon, Inc and changed its name to Enzon Pharmaceuticals, Inc. in December 2002. Enzon Pharmaceuticals, Inc. was incorporated in 1981 and is headquartered in Cranford, New Jersey.

Heyu Biological Technology OTCMKTS:HYBT

$0.14 0.00 (0.00%)

As of 08/5/2026

Hong Chang Biotechnologies (HK) Limited was incorporated in 2023 and is based in Kowloon, Hong Kong. Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Zengqiang Investment Limited. As of September 4, 2023, Hong Chang Biotechnologies (HK) Limited operates as a subsidiary of Heyu Biological Technology Corporation.

Phio Pharmaceuticals NASDAQ:PHIO

$1.06 -0.01 (-0.93%)

Closing price 04:00 PM Eastern

Extended Trading

$1.04 -0.02 (-1.42%)

As of 06:30 PM Eastern

Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells' ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors. It is also developing PH-894, an INTASYL compound in IND enabling studies to silence BRD4, a protein that controls gene expression in both T cells and tumor cells, effecting the immune system and the tumor. The company was formerly known as RXi Pharmaceuticals Corporation and changed its name to Phio Pharmaceuticals Corp. in November 2018. Phio Pharmaceuticals Corp. was incorporated in 2011 and is based in Marlborough, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENZN, HYBT, BLRX, and PHIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENZN, HYBT, BLRX, and PHIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENZN, HYBT, BLRX, and PHIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENZN, HYBT, BLRX, and PHIO Company Descriptions

BioLineRx NASDAQ:BLRX

Enzon Pharmaceuticals OTCMKTS:ENZN

Heyu Biological Technology OTCMKTS:HYBT

Phio Pharmaceuticals NASDAQ:PHIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ENZN, HYBT, BLRX, and PHIO Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ENZN, HYBT, BLRX, and PHIO Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ENZN, HYBT, BLRX, and PHIO Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ENZN, HYBT, BLRX, and PHIO Company Descriptions

BioLineRx NASDAQ:BLRX

Enzon Pharmaceuticals OTCMKTS:ENZN

Heyu Biological Technology OTCMKTS:HYBT

Phio Pharmaceuticals NASDAQ:PHIO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools